<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03344887</url>
  </required_header>
  <id_info>
    <org_study_id>20170477-01H</org_study_id>
    <nct_id>NCT03344887</nct_id>
  </id_info>
  <brief_title>An Innovative Trial Assessing Donor Sex on Recipient Mortality</brief_title>
  <acronym>iTADS</acronym>
  <official_title>An Innovative Trial Assessing Donor Sex on Recipient Mortality (iTADS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Blood Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The iTADS trial will test an important blood donor characteristic - donor sex - to see&#xD;
      whether male donor blood leads to a greater benefit for transfusion recipients compared to&#xD;
      female donor blood.&#xD;
&#xD;
      The trial will help determine how the investigators can tailor the selection of blood donors&#xD;
      based on donor characteristics (e.g. sex) to further improve the safety and optimize the&#xD;
      clinical benefit of blood products in Canada.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators have designed an innovative pragmatic randomized trial that will allocate&#xD;
      transfusion recipients to receive either only male or only female donor transfusions.&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      To confirm that a transfusion strategy of receiving male donor RBC (Red Blood Cell) units&#xD;
      only will improve survival compared to a transfusion strategy of female donor RBC units in&#xD;
      all hospital patients requiring a transfusion.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        1. To assess effects of male RBC units on major morbidities (cancer, infection, end-organ&#xD;
           damage)&#xD;
&#xD;
        2. To assess effects across major patient subgroups (major surgery, intensive care,&#xD;
           oncology)&#xD;
&#xD;
        3. To assess the effect of female donor pregnancy history on recipient transfusion outcome&#xD;
&#xD;
        4. To build capacity to conduct large innovative prospective pragmatic clinical trials in&#xD;
           transfusion medicine using routinely collected clinical and administrative information.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 4, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Actual">January 23, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Measured from date of first randomization to date of death or end of study 2 years from first patient enrollment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>30 days, 3 months, 6 months and 1 year</time_frame>
    <description>Measured from date of first randomization to date of death or end of study 2 years from the first patient enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>2 years</time_frame>
    <description>Number of days admitted to hospital for the treatment of anemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New ICU admission</measure>
    <time_frame>2 years</time_frame>
    <description>Occurrence of ICU admission(s) once discharged for the treatment of anemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-hospitalization</measure>
    <time_frame>2 years</time_frame>
    <description>Occurrence of additional hospital admission(s) once discharged for the treatment of anemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health system costs</measure>
    <time_frame>2 years</time_frame>
    <description>The cost of the treatment of anemia and any related downstream health care resources.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of new cancer</measure>
    <time_frame>2 years</time_frame>
    <description>The number of new cancer diagnoses, not present during the initial treatment of anemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of cancer</measure>
    <time_frame>2 years</time_frame>
    <description>The number of repeat cancer diagnoses, diagnosed previous to the initial treatment of anemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection rates</measure>
    <time_frame>2 years</time_frame>
    <description>Methicillin-resistant Staphylococcus aureus and Clostridium difficile for hospital-acquired infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New occurrence of hemodialysis</measure>
    <time_frame>2 years</time_frame>
    <description>For severe chronic renal failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarctions</measure>
    <time_frame>2 years</time_frame>
    <description>For cardiac events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8850</enrollment>
  <condition>Red Blood Cell Transfusion</condition>
  <arm_group>
    <arm_group_label>RBC Transfusion from male donor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For the treatment of anemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RBC Transfusion from female donor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For the treatment of anemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RBC Transfusion from male donor</intervention_name>
    <description>Patients requiring an RBC transfusion for the treatment of anemia will receive products from a male donor at initial and any subsequent hospitalizations during the trial period.</description>
    <arm_group_label>RBC Transfusion from male donor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RBC Transfusion from female donor</intervention_name>
    <description>Patients requiring an RBC transfusion for the treatment of anemia will receive products from a female donor at initial and any subsequent hospitalizations during the trial period.</description>
    <arm_group_label>RBC Transfusion from female donor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients (excluding neonates) requiring one or more allogeneic RBC transfusions&#xD;
             for the treatment of anemia will be included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients that do not have a valid Ontario Health Insurance Plan (OHIP) number at time&#xD;
             of first transfusion&#xD;
&#xD;
          -  Patients that require emergent release of a RBC transfusion and in whom emergency&#xD;
             randomization could not be completed&#xD;
&#xD;
          -  Patients with complex antibody profile in which it is impossible to match RBC units&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michaël Chassé</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dean Fergusson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Tinmouth</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ottawa Hospital - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anemia</keyword>
  <keyword>donor sex</keyword>
  <keyword>prospective blinded pragmatic randomized</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

